BioChain In-licenses China Rights to Colorectal Cancer Test
publication date: Oct 31, 2013
BioChain, a US-China clinical diagnostics company, acquired exclusive China rights to the Septin9 in vitro diagnostic test for colorectal cancer from Epigenomics AG of Germany. As part of the deal, BioChain will buy $1.3 million Epigenomics stock. It will also underwrite a China clinical trial of the device to obtain CFDA approval, for which it agreed to buy 5,000 Epi proColon® tests. In China, BioChain is located in Beijing. More details....
Stock Symbol: (F: ECX, OTC: EPGNY)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.